AI Takes on Motor Neuron Disease

In 2026, researchers at the UK Dementia Research Institute in Edinburgh are using artificial intelligence to speed up the search for treatments for neurological conditions such as motor neuron disease (MND). By combining patient data—voice recordings, iris scans, and blood samples—with lab‑grown brain cells, the team hopes to discover whether existing, approved drugs could be repurposed.

Using AI to identify disease patterns and predict suitable medicines could reduce the testing timeline from decades to years. The Institute’s MND‑SMART trial is an example of this approach, testing several drugs simultaneously rather than comparing one treatment to a placebo.

Steven Barrett, a 10‑year MND patient, shares his experience: “MND strips you of who you are. It rips any sense of future I had planned.” Despite the tragedy, he sees the trial as a "bright light" of hope, saying that the research could help others even if it does not help him personally.

Patients donate voice recordings, iris scans and blood samples to grow stem‑cell‑derived neurons. Algorithms then screen over 1,500 existing drugs, searching for those that could convert the neurological disease signature into a healthy one. Drugs identified by the AI are moved into clinical trials for people like Barrett.

Prof Siddarthan Chandran, chief executive of the Institute, explains that because many drugs already exist and are approved for other uses, repurposing them could accelerate availability. He notes that the complexity of the brain means new technologies—AI, robotics, sophisticated lab equipment—are essential for this work.

While setbacks have occurred in similar research—such as the limited impact of amyloid‑removing drugs for Alzheimer’s—scientists remain optimistic that AI will drive a tipping point in neurological research. If successful, affordable, effective MND treatments could become a reality much sooner than the 10‑plus‑year timelines typical of new drug development.

With AI combing vast medical data, the UK Dementia Research Institute is carving a new path toward faster, more cost‑effective treatments for patients suffering from motor neuron disease and other neurodegenerative illnesses.